As you might know, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) last week released its latest second-quarter, and things did not turn out so great for shareholders. Earnings missed the mark badly, with revenues of US$9.0m falling 30% short of expectations. Losses correspondingly increased, with a US$0.43 per-share statutory loss some 13% larger than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

Taking into account the latest results, the most recent consensus for Monte Rosa Therapeutics from seven analysts is for revenues of US$53.7m in 2026. If met, it would imply a huge 87% increase on its revenue over the past 12 months. Losses are expected to be contained, narrowing 14% from last year to US$1.62. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$44.5m and losses of US$1.66 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady.

The consensus price target fell 18% to US$28.50as the analysts signal that ongoing losses are likely to weigh on the stock price. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Monte Rosa Therapeutics, with the most bullish analyst valuing it at US$37.00 and the most bearish at US$25.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Monte Rosa Therapeutics' growth to accelerate, with the forecast 249% annualised growth to the end of 2026 ranking favourably alongside historical growth of 69% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 23% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Monte Rosa Therapeutics to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Monte Rosa Therapeutics' future valuation.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Monte Rosa Therapeutics analysts - going out to 2028, and you can see them free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.